RXi Pharmaceuticals Corp (NASDAQ:RXII) has received an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating.
Brokerages have set a twelve-month consensus target price of $2.00 for the company and are anticipating that the company will post ($0.45) EPS for the current quarter, according to Zacks. Zacks has also given RXi Pharmaceuticals an industry rank of 101 out of 255 based on the ratings given to its competitors.
A number of brokerages recently issued reports on RXII. HC Wainwright set a $3.00 price objective on shares of RXi Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, August 15th. ValuEngine upgraded shares of RXi Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 2nd.
RXi Pharmaceuticals (NASDAQ:RXII) last posted its earnings results on Tuesday, August 14th. The biotechnology company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.16. The company had revenue of $0.06 million during the quarter, compared to the consensus estimate of $0.02 million. On average, equities research analysts forecast that RXi Pharmaceuticals will post -1.55 EPS for the current fiscal year.
An institutional investor recently bought a new position in RXi Pharmaceuticals stock. SG Americas Securities LLC acquired a new stake in RXi Pharmaceuticals Corp (NASDAQ:RXII) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 118,387 shares of the biotechnology company’s stock, valued at approximately $228,000. SG Americas Securities LLC owned about 2.78% of RXi Pharmaceuticals at the end of the most recent reporting period. 8.87% of the stock is currently owned by institutional investors and hedge funds.
RXi Pharmaceuticals Company Profile
RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye.
Read More: Stock Symbols and CUSIP Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for RXi Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.